Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Wave Life Sciences Ltd. Director's Dealing 2025

Dec 11, 2025

31900_dirs_2025-12-10_b4b87295-f5f6-4b33-8916-862870afd219.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2025-12-08

Reporting Person: Moran Kyle (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-12-08 Ordinary Shares M 60000 $2.83 Acquired 149218 Direct
2025-12-08 Ordinary Shares S 60000 $13.20 Disposed 89218 Direct
2025-12-08 Ordinary Shares M 100000 $3.14 Acquired 189218 Direct
2025-12-08 Ordinary Shares S 50000 $15.00 Disposed 139218 Direct
2025-12-08 Ordinary Shares S 50000 $13.20 Disposed 89218 Direct
2025-12-08 Ordinary Shares M 50000 $4.75 Acquired 139218 Direct
2025-12-08 Ordinary Shares S 50000 $18.00 Disposed 89218 Direct
2025-12-09 Ordinary Shares M 36000 $8.17 Acquired 125218 Direct
2025-12-09 Ordinary Shares S 36.000 $20.25 Disposed 89218 Direct
2025-12-09 Ordinary Shares M 50000 $10.48 Acquired 139218 Direct
2025-12-09 Ordinary Shares S 50000 $20.025 Disposed 90365 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-12-08 Share Option (right to buy) $2.83 A 60000 Disposed 2032-07-25 Ordinary Shares (60000) Direct
2025-12-08 Share Option (right to buy) $3.14 A 100000 Disposed 2032-01-01 Ordinary Shares (100000) Direct
2025-12-08 Share Option (right to buy) $4.75 A 50000 Disposed 2033-02-17 Ordinary Shares (50000) Direct
2025-12-09 Share Option (right to buy) $8.17 A 36000 Disposed 2030-03-03 Ordinary Shares (36000) Direct
2025-12-09 Share Option (right to buy) $10.48 A 50000 Disposed 2031-02-01 Ordinary Shares (50000) Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025.

F2: These share options are fully vested.

F3: The share option represented a right to purchase a total of 175,000 ordinary shares that vest as to 25% of the shares on January 1, 2023 and vests as to an additional 6.25% of the shares quarterly thereafter until January 1, 2026.

F4: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.00 to $15.045 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F5: The share option represented a right to purchase a total of 272,200 ordinary shares that vest as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027.

F6: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $20.00 to $20.22 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F7: Includes 1,147 ordinary shares acquired on July 14, 2025, under the issuer's 2019 Employee Share Purchase Plan.